In the case of AML, exosomes from normal or AML bone marrow stromal cells (BMSCs) protect the leukemic cells owing to FLT3-ITD mutations against cytarabine; however, only AML-BMSC-exosomes impart protection against FLT3 inhibitor treatment [218]. The gene discussed is FLT3; the disease is acute myeloid leukemia.